Trial · NCT00748579
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
NCT00748579, Phase 2, Terminated, Cytokinetics; results first posted 2010-08-23
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency. Trials, record NCT00748579. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00748579
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
- NCT number
- NCT00748579
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Cytokinetics
- Conditions
- Heart Failure
- Interventions
- CK-1827452, CK-1827452
- First posted
- 2008-09-08
- Last updated
- 2020-01-21
- Results first posted
- 2010-08-23
- Limitations and caveats
- Inadequate enrollment led to early termination of study and insufficient number of patients for analysis.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of CK-1827452 on Myocardial Efficiency, Defined as the Ratio of Ventricular Performance to Myocardial Oxygen Consumption. | 1 day | Measure the effect CK-1827452 on hemodynamics and energetic measures of ventricular performance, myocardial oxygen consumption, and myocardial efficiency (the ratio of ventricular performance to myocardial oxygen consumption), in patients with clinical heart failure. |
| Secondary | Effects of CK-1827452 on Ventricular Performance | 1 day | Measure the effect of CK-1824752 on ventricular performance |
| Secondary | Effects of CK-1827452 on Myocardial Oxygen Consumption | 1 day | Measure the effect of CK-1824752 on myocardial oxygen consumption |
| Secondary | Effects of CK-1827452 on Pressure-volume Relationships | 1 day | Measure the effect of CK-1824752 on pressure-volume relationships |
| Secondary | Effects of CK-1827452 on Systolic Ejection Time | 1 day | Measure the effect of CK-1824752 on systolic ejection time |
| Secondary | Effects of CK-1827452 on Invasively Measured Hemodynamics, Including Filling Pressure and Cardiac Output | 1 day | Measure the effect of CK-1824752 on invasively measured hemodynamics, including filling pressure and cardiac output |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Effect of CK-1827452 on Myocardial Efficiency, Defined as the Ratio of Ventricular Performance to Myocardial Oxygen Consumption. | 1 day | Study was terminated due to poor enrollment; 2 participants completed the study. Data quantity was insufficient to analyze or draw conclusions. | ||
| SECONDARY | Effects of CK-1827452 on Ventricular Performance | 1 day | No data displayed because Outcome Measure has zero total participants analyzed. | ||
| SECONDARY | Effects of CK-1827452 on Myocardial Oxygen Consumption | 1 day | No data displayed because Outcome Measure has zero total participants analyzed. | ||
| SECONDARY | Effects of CK-1827452 on Pressure-volume Relationships | 1 day | No data displayed because Outcome Measure has zero total participants analyzed. | ||
| SECONDARY | Effects of CK-1827452 on Systolic Ejection Time | 1 day | No data displayed because Outcome Measure has zero total participants analyzed. | ||
| SECONDARY | Effects of CK-1827452 on Invasively Measured Hemodynamics, Including Filling Pressure and Cardiac Output | 1 day | No data displayed because Outcome Measure has zero total participants analyzed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Mid Dose CK-1827452 (Cohort 1) | 2 | |
| Overall Study | STARTED | High Dose CK-1827452 (Cohort 2) | 0 | |
| Overall Study | COMPLETED | Mid Dose CK-1827452 (Cohort 1) | 2 | |
| Overall Study | COMPLETED | High Dose CK-1827452 (Cohort 2) | 0 | |
| Overall Study | NOT COMPLETED | Mid Dose CK-1827452 (Cohort 1) | 0 | |
| Overall Study | NOT COMPLETED | High Dose CK-1827452 (Cohort 2) | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Troponin Increased | Investigations | Mid Dose CK-1827452 (Cohort 1) | 2 | 2 | 2 |
| other | Troponin Increased | Investigations | High Dose CK-1827452 (Cohort 2) | 0 | 0 | 0 |
| other | Supraventricular Tachycardia | Cardiac disorders | Mid Dose CK-1827452 (Cohort 1) | 1 | 2 | 1 |
| other | Supraventricular Tachycardia | Cardiac disorders | High Dose CK-1827452 (Cohort 2) | 0 | 0 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Mid Dose CK-1827452 (Cohort 1) | ||
| Total, all-cause mortality | High Dose CK-1827452 (Cohort 2) | ||
| Total, other adverse events | Mid Dose CK-1827452 (Cohort 1) | 2 | 2 |
| Total, other adverse events | High Dose CK-1827452 (Cohort 2) | 0 | 0 |
| Total, serious adverse events | Mid Dose CK-1827452 (Cohort 1) | 0 | 2 |
| Total, serious adverse events | High Dose CK-1827452 (Cohort 2) | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00748579
GET https://conductscience.org/api/trials/v1/NCT00748579/registered